Scott Dunseth Myers
Chief Executive Officer at Viridian Therapeutics Inc.
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 9 years
- Director since
- 2023
9 years of board service in total across 3 boards, counting each seat separately. Longest: Cartesian Therapeutics Inc., 3 years.
Cartesian Therapeutics Inc.
Director
Viridian Therapeutics Inc.
Director · Chief Executive Officer
Zentalis Pharmaceuticals Inc.
Director
Chief executive roles
Viridian Therapeutics Inc.
· Chief Executive Officer
2023 – 2023
· Former
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 13, 2024 | Zentalis Pharmaceuticals Inc. | Grant or award | +260,192 | — | — |
| Apr 12, 2023 | Viridian Therapeutics Inc. | Open-market purchase | +4,000 | $25.37 | $101,480 |
| Mar 13, 2023 | Viridian Therapeutics Inc. | Open-market purchase | +5,500 | $29.15 | $160,325 |
| Feb 6, 2023 | Viridian Therapeutics Inc. | Grant or award | +250,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.